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CONNEDCT, A MOBILE-FIRST FRAMEWORK FOR  
CLINICAL ELECTRONIC DATA CAPTURE 
CALEB J. RUTH 
ABSTRACT 
 Paper-based data capture has long served as the primary means of 
collecting research data and continues to be the dominant means of data capture 
through the present day. Despite inertia with adopting information technology 
in clinical research, electronic methods of information capture have important 
benefits over traditional, paper-based methods. Electronic Data Capture (EDC) 
systems can provide integrated error checking, protocol enforcement, decision 
support, automated randomization, and quicker access to data and results. As 
EDC systems become more accessible and resourceful, EDC has begun to replace 
paper-based data capture. Meanwhile, mobile computing, utilizing smartphones 
and tablets, has become commonplace in business and our everyday lives. Many 
EDC solutions support mobile devices, yet few were conceived with a “mobile-
first” design philosophy and fewer support extensive study protocol-support 
features. A significant amount of clinical research is conducted in geographic 
regions with limited or no Internet access such as impoverished and remote 
communities. Current EDC solutions remain challenging to use in these contexts. 
 
 vi 
While EDC is an increasingly important tool for clinical research, when EDC 
solutions are built on web-centric architectures, the lack of Internet coverage 
means that researchers often need to fall back on paper-based data capture 
methods or build expensive, custom EDC tools. A customizable Mobile 
Electronic Data Capture (mEDC) framework with an asynchronous data 
transport layer will better meet the needs of distributed studies in resource-
limited, geographical areas. I developed ConnEDCt, a full-featured mEDC 
application that is customizable for longitudinal study protocols, with 
regulatory-compliant security, auditability and an asynchronous data transport 
model. ConnEDCt is adaptable to different study protocols, has extensive study 
protocol-support built-in, and supports on- or off-line data synchronization to a 
central data repository. ConnEDCt focuses on mobility and is designed to serve 
the needs of complex clinical research studies in regions where other EDC 
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As fluorescent lights flickered and flies buzzed, my eyes traced the path of 
the catheter as it emerged from a hole drilled in the man’s bandaged head and 
lead to an open glass jar under his hospital cot. His swollen brain was squeezing 
cerebral-spinal fluid from the ventricles in his brain. The murky liquid gathered 
in the glass jar under his bed. This was the late 1990’s in post-Soviet Eastern 
Europe. The man in front of me on the cot was a victim of head trauma, an 
everyday accident for ordinary people. He was one of several similar patients in 
the ICU of this teaching hospital in Ljubljana, Slovenia. The hospital was 
struggling to provide adequate care.  
The neurosurgeons and other attending physicians gathered around the 
patient and reviewed his medical chart on a clipboard while a neurosurgery 
resident used a new IBM ThinkPad laptop to enter medical data into the 
Traumatic Brain Injury Survey database (TBIS). The TBIS program was 
conducted to support an evidence-based treatment protocol, the Guidelines for 
the Management of Traumatic Brain Injury. I, along with the clinical team, built 





Figure 1.1. The author demonstrating the Traumatic Brain Injury Survey (TBIS) EDC tool 
to a group of physicians c. 1999 
 
Research fellows, usually neurosurgery hospital residents, entered 
comprehensive data relevant to brain injury for up to 12 months post-injury into 
TBIS. The database captured the data and provided decision support, using 
protocols published in the Guidelines. Based on captured data, TBIS could 
highlight when a medical intervention - like drilling a hole in the cranium to 
relieve intra-cranial pressure - was recommended. The TBIS project provided 
medical training, a laptop with the TBIS app, a flatbed scanner for radiology 
films, and a dial-up Internet connection. The project goals were to train the 
Guidelines, monitor compliance, and validate and refine the Guidelines in 
follow-up analysis. The data was regularly delivered electronically to New York 




The TBIS program was deployed in teaching hospitals distributed roughly 
linearly from Estonia on the Baltic Sea to Croatia on the Adriatic Sea, a north-
south slice right through the middle of Europe. TBIS operated for several years 
and spawned three distinct data capture tools, including the primary clinical 
data capture app, an expanded version, and a tele-radiology diagnostic review 
app. It inspired new head trauma research programs in the U.S. and Europe. We 
developed these tools in an age of dial-up Internet when research data was 
almost exclusively captured on paper, Netflix was a DVD-by-mail service, 
Google was still an academic research project, and Wikipedia and Facebook 
hadn’t yet been created. TBIS showed that, despite limited resources, a database 
system with support from remote specialists could make an impact in the care of 
patients in the present and in the future.  
This is how my adventure in Health Information Technology (HIT) began 
and how I came to believe in its value to improve the quality of medical science. I 
don’t know the outcome of the man I saw in the hospital in Ljubljana more than 
20 years ago, but I’m confident that the research that his participation 
contributed to has helped trauma surgeons successfully treat innumerable 
patients of head trauma since then. Research coupled with technology has 




Today paper-based data capture (PDC) is still common because of low up-
front costs, and few technical requirements. A pen and paper will do. However, 
it is also error-prone, carries a high risk of data-loss, takes time to retrieve from 
the field, and requires transcription in order to perform data analysis. Therefore, 
PDC is usually more expensive than it first appears when the total cost is tallied. 
Electronic Data Capture (EDC) can solve many of the issues related to PDC and 
provide additional benefits. 
We now have a society accustomed to portable computing devices, such 
as phones and tablets, and a rich environment of HIT. Regulations are maturing 
to cope with privacy and ethics in HIT. Clinical research is a well-defined field 
that has developed over many hundreds of years. Meanwhile, informatics 
implementations for clinical research date from at least the 1980s. Nonetheless, it 
is only relatively recently that informatics systems have advanced to combine 
portability with platforms that support complex study protocols. Drs. Embi and 
Payne pointed out that “Clinical researchers are faced with significant and 
increasingly complex workflow and information management challenges. 
…effective and efficient information access is critical to any solution to the many 
challenges faced by the domain.”[1] A complex clinical study protocol will often 




randomization, and clinical visit scheduling.  These are complex design 
challenges for the clinical researcher as well as the information scientist. 
In this thesis I report on the development and utilization of the ConnEDCt 
electronic data capture framework that helps structure the study protocol design 
process while enforcing protocol compliance and providing other benefits to 
clinical research teams. ConnEDCt prioritizes tablet computing and portability 
by design. A balance of app capability, ease of use, careful protocol design, some 
specialized programming, and flexibility – in short thoughtfulness – are the keys 
to connect the data to the research. 
1.1. Background 
Electronic data capture (EDC) systems are designed to facilitate structured 
data input into an electronic storage system for use with clinical research. “The 
main advantages of EDC would be to enter, review, and analyze data in real-
time and to implement online data validation checks to assure data quality.” [2] 
However, paper-based case report forms (CRFs) are often still used in clinical 
research. Limiting factors such as cost, technical requirements, or perceived 
shortcomings can hinder EDC implementation. Many EDC solutions require a 
full-time Internet connection to connect to a web site or have limited 




that tablets and mobile phones provide at the point of data capture (POC). When 
internet access is limited investigators often will fall back on paper-based CRFs. 
Data captured on paper must later be re-entered from the paper-based CRFs into 
an EDC system.[3] Utilizing paper-based CRFs and performing secondary entry 
into an EDC system erases many of the benefits of EDC such as error reduction, 
protocol enforcement, and faster data availability.  
Recently, mobile devices such as tablets and mobile phones have begun to 
be used for EDC. Mobile EDC (mEDC) has the potential to overcome many of the 
limitations of standard EDC. However, current implementations of mEDC are 
still limited to custom systems or systems that require full-time Internet. Custom 
solutions require access to skilled, possibly expensive programmers and reliable 
internet access is still unavailable in much of the rural and developing world. [4, 
5] These limitations can prohibit the use of EDC especially in poor, rural 
communities where research is most needed. 
In 2015 the Mehta Research Group (MRG) of Cornell University was 
hitting these limitations while attempting to find an EDC solution for their 
research projects running off the grid in rural and under-developed areas in 
India and South America. MRG contacted this author to develop a system that 




exists for a mobile-EDC platform designed for sophisticated, longitudinal 
research that can operate in regions and communities that are off the modern, 
information grid. We developed a design for a framework that would be re-
usable for multiple clinical studies and operate on mobile devices with limited 
internet access. This framework, named ConnEDCt, would support accepted 
clinical study protocol methodologies described below. 
1.1.1. The Clinical Study Protocol 
 “The concept of a protocol is fundamental”[6] to clinical research and 
EDC. Data capture and supporting the study protocol are the two essential 
functions of clinical EDC. A clinical study protocol is a written document that 
includes the research objectives, scientific background, study design, and 
methods. [7] A research team led by a principal investigator (PI) designs the 
protocol while an Institutional Review Board (IRB) reviews and approves the 
protocol to ensure good research and ethical practices. [8] The aspects of a 
clinical study protocol that are relevant to data capture and informatics include 





1.1.2. Case Report Forms 
A Case Report Form (CRF) is the basic design element of clinical research. 
The CRF is the tool used to collect participant data in a clinical study. [9] A CRF 
consists of a collection of related variables to be entered by interviewers or study 
participants. A single study is likely to rely on multiple CRFs organized by 
clinical topic or workflow logic. Researchers determine in advance what data 
elements will be captured. To facilitate the interview process, as well as later data 
analysis, CRFs are designed when possible with numeric or coded responses that 
are selected from predefined lists. [6] The design of CRFs is an in-depth process 
involving both technical and research team members and is a key step in 
ensuring the quality of the collected data. Effective CRF design includes attention 
to clarity of language, concise coding, layout design, organization, and workflow 
of data collection. [7] Various types of CRFs may collect baseline data, laboratory 
results, clinical observations, follow-up, and outcome data. 
1.1.3. The Study Schema 
The study schema is the data abstraction of the clinical study protocol and 
will define and enforce the workflow within the context of the EDC tool. The 
study schema defines when and how frequently the CRFs are to be completed 




may define a single participant encounter with one or more CRFs. A Study 
Schema of a longitudinal study may define a screening visit, a baseline clinical 
assessment, a number of midline assessments, and an outcome assessment. [7] 
The initial encounter with a potential study participant will include obtaining 
informed consent and assessing eligibility criteria. A baseline clinical assessment 
may collect demographic and initial clinical data. Midline assessments will 
record comparison data during the course of the study. The outcome assessment 
will collect the final data points and markers of the study. When data capture 
will be performed by different research staff or for different conceptual areas 
during one encounter, the questions are separated into multiple CRFs. 
Administrative staff may conduct the initial interview and capture demographic 
information while clinical staff may perform clinical screening and assessments. 
In future visits nursing staff may enter some CRFs, while physicians and 
laboratory staff complete others. 
Adverse events, withdrawal from the study, or other emergent events 
may occur at any time during the course of the study and must be recorded. [6] 
These unscheduled events fall out of the predefined schedule of events, but still 
are accounted for in the Study Schema. 




becomes both a design tool for EDC implementation as well as a compliance 
enforcement tool supporting data capture while the study is conducted. 
Richesson and Andrews referred to the informatics structure that defines which 
CRFs are to be filled out during which time points as an “Event-CRF Cross 
Table” [6]. In informatics terms this schedule of when to present CRFs for data 
capture is abstracted as a join table between the CRF table and the Event table. 
This table matches CRFs to Events in a many-to-many relationship. The benefit 
to the research assistant (RA) or other data entry staff is that when viewing a 
particular encounter in the Study Protocol, only the forms for that encounter will 
be presented. It will not be possible for the RA to complete a form that is not 
scheduled for that encounter. Conversely, all the forms scheduled for an 
encounter will be presented to the RA. Completing the forms scheduled for a 
visit can therefore be enforced.  
1.1.4. Informed Consent 
History documents many cases of tragic effects when medical researchers 
exploited patients by denying them information and the opportunity to consent 
to participate in clinical experiments. Section 3.1 Ethics and Governing Regulations 
details several of these cases of exploitation and abuse. In response to this 




become a standard for ensuring voluntary participation in clinical research. 
The United States government has developed regulations to protect the 
rights of participants in clinical research. These regulations are referred to as 
“The Common Rule” and are explored in depth in Chapter 3. Other nations have 
developed their own regulations or follow the U.S. rules.  
The purpose of informed consent is to protect human subjects enrolled in 
clinical studies. [8] Government regulations in the U.S. and other countries 
require that researchers inform participants in a clinical study of the risks of 
participation and voluntarily grant consent to be included in the study. Informed 
consent procedures may vary based on study protocols, nation-specific legal 
regulations, and the age of participants. Informed consent may occur multiple 
times during the course of a study and include consent for different facets of the 
study, for example discrete consents for participation in a study and collection of 
biological samples. Assent by a minor will require the consent of a legal 
guardian. Consent given by illiterate participants may require a third-party 
witness. In all cases informed consent forms must include information on the 
study, the potential risks and benefits of participation, and capture proof – such 




1.1.5. Eligibility Criteria and Enrollment 
Clinical Decision Support (CDS) is another significant benefit of 
computerized clinical systems. With access to data, computer systems can apply 
algorithms to make determinations and recommendations toward various 
clinical goals. CDS has been used in clinical settings since as early as the 1980s 
and eligibility determination has been a common usage. [6] Eligibility or 
inclusion criteria are decided by the study authors and translated into computed 
algorithms. Automating the algorithms can speed the evaluation and improve 
the accuracy of participant eligibility. Efficient eligibility determination can 
improve the quality and lower the costs of participant recruitment. At the most 
basic level Boolean eligibility requirements are defined and participants are 
evaluated based on true or false determinations for each criterion. If the answers 
to one or more of the criteria are false, then the participant will be ineligible. If all 
the criteria are met, then the participant will be eligible and can be enrolled in the 
study.  
1.1.6. Randomization and Blinding 
If a study involves treatments, participants will often be randomly 
divided into multiple, blinded study groups. Randomization ensures a known 




that the assignment will be unpredictable. Often this will be an equal chance 
between a control and one or more active interventions. Other times the chance 
will be designed to be unequal. In all cases the probability of assignment will be 
known but the actual assignment will be unpredictable.[11] To maintain the 
integrity of a study the investigator may utilize one of two popular approaches. 
Single-blind design ensures the subject is unaware of the study group 
assignment. Double-blinding ensures that neither participants nor researchers 
know the study group assignment. 
Double-blinding ensures that study participants and those directly 
involved in the outcomes of the study or direct involvement with participants do 
not know the assignment of the study group to a particular intervention or 
control. Blinding techniques minimize bias that can influence additional clinical 
interventions or outcome evaluation. Investigators face internal and external 
pressures to influence the group assignment process. Participants may pressure 
an investigator to be included in the active study group over the control group. 
Investigators themselves may consciously or unconsciously impose bias for a 
variety of reasons, including the honest desire to improve the health outcomes of 
participants. Studies have shown the real, confounding effects of unblinded 




blinding are entwined and integral to effective clinical research. 
The randomization process needs to be protected so that assignments are 
effectively random and blinded. PDC requires strict manual controls. The “sealed 
envelope technique” is one common manual randomization control that involves 
random assignments that are created in advance and unsealed only when an 
eligible participant is enrolled in the study.[12] EDC allows machines to enforce 
randomization and blinding by automating the generation of randomization 
tables and the assignment of participants to blinded study groups. 
Let’s briefly explore various study designs and techniques of 
randomization. The simplest type of interventional study will include a control 
group and an active group. Block randomization would ensure that an equal 
number of participants would be assigned to each group after a certain number 
of participants have been enrolled.[11] For example in a randomized controlled 
trial (RCT) with two study groups, for every 20 participants enrolled (the block 
size is 20), 10 would be assigned to group A, and 10 would be assigned to group 
B. A more advanced trial might have multiple active groups and a different 
proportional balance. In this case it may be desirable to control the percentages 
assigned to each study group (ie 30%, 30%, 40%). So, with a block size of 20, 




have 8 participants. 
Stratification is a technique to control confounding of the study objective. 
It involves “separating a sample into several subgroups according to specific 
criteria”[13] and ensures that a predictor of outcome can be evenly distributed 
among study groups.[12] For example if age were known to be associated with 
outcome, simple block randomization could result in an imbalance of age among 
study groups, with most elderly participants in one treatment group and 
younger participants in the other group. This could have a confounding effect on 
the study. Stratification would control for this and balance distribution by age 
group. Other confounding factors could be geography, sex, or pre-existing 
medical conditions.[11] Effectiveness must be protected with randomization 
techniques. Blocks and strata must be sized appropriately to ensure effective 
randomization. Too many strata may leave many blocks unfilled.[11, 12] 
Other randomization techniques include cluster randomization, matched 
pairs, unequal group allocation, adaptive randomization, and pseudo-
randomization.[11, 12] Randomization techniques can also be applied within the 
otherwise fixed form schedule protocol. Randomized CRF serial sampling will 
schedule one or more CRFs at a randomized point in the study timeline. A 




participants within the overall study cohort on whom to capture more extensive 
data. Documentation of the randomization process is essential for auditing the 
integrity of the process as well as certifying which group received which 
treatment. A well-designed study will ensure effective randomized assignment 
of participants to blinded study groups.  
1.2. Thesis Statement 
A mobile electronic data capture framework with support for complex 
study protocols that also functions with limited internet access will better meet 
the needs of clinical researchers working on distributed studies in resource-
constrained geographical areas than other available EDC platforms. This thesis 
will explore the architecture of ConnEDCt, an EDC framework built by the 
author, and case studies of seven clinical research investigations that have used 
ConnEDCt as their primary EDC tool and provided valuable input toward the 
development of the framework. ConnEDCt supports complex features of 
longitudinal study protocols, requires minimal training to use, operates with 
limited internet connectivity, is regulatory-compliant, and operates on mobile 




1.3. Contribution of the Thesis 
The original contributions of this research work include the development 
of the ConnEDCt app, a framework and platform for mobile electronic data 
capture to support complex clinical studies in remote areas. ConnEDCt is built 
for clinical investigators to improve data quality of their research in challenging 
environments. ConnEDCt has a client component that runs on desktop and 
mobile platforms and a server component to centralize data. ConnEDCt has been 
used by five clinical investigations including cohort studies, cross-sectional 
surveys, and clinical trials for over 3,000 participants with over 13,000 participant 
encounters and over 55,000 completed case report forms. ConnEDCt is a full-
featured mEDC solution that provides complex protocol support and easy 
extensibility for additional clinical research requirements. It allows investigators 
with limited assistance from programmers to implement case report forms, data 
validation, automated eligibility assessment, and scheduled events. ConnEDCt 
fills a gap in available EDC tools with support for complex protocols, and 
investigations in geographical areas with limited or no Internet availability. 





1.4. Organization of the Thesis 
In this thesis, we provide a brief encapsulation of the author’s prior 
experience in clinical research; an overview of clinical study protocols; and the 
thesis statement in Chapter 1. Chapter 2 discusses the history of electronic data 
capture and mobile computing in clinical settings. Chapter 3 explores in detail 
ethical concerns around clinical research and government regulations to protect 
human research subjects. Chapter 4 lays out the detailed architecture of the 
ConnEDCt software platform including database schema, data lifecycle, 
functional components, implementation of new studies, system deployment, and 
data capture workflow. Chapter 5 examines five case studies of ConnEDCt 
implementations for clinical studies. Chapter 6 explores planned future 
enhancements and lessons learned, and Chapter 7 draws conclusions about the 





2. EXISTING LITERATURE 
2.1. Electronic Data Capture 
Scientific and clinical studies mostly continue to rely on paper-based data 
capture (PDC) with EDC gaining more and more momentum. As computers 
became widely used for statistical analysis, double data entry of paper CRFs into 
spreadsheets or databases became a routine step in data capture. EDC is being 
adopted at a greater rate as the availability of computers, software, and the 
Internet keeps growing. When implemented well, EDC has some obvious 
benefits over PDC. Shantala, B., K. Binny, and M.S. Latha demonstrated that 
electronic CRFs eliminate redundant data entry, reduce data entry errors, 
improve data quality, and standardize data formats.[9] Despite the evident 
advantages, the perceived cost and limited technical capability often remain as 
barriers to adoption of EDC. This is especially true for small- to medium-scale 
studies without institutional or enterprise financial and technical support. As we 
will see from other prior research, the benefits of EDC in data quality and overall 
financial cost are real and justifiable. 
Weber, et al., in a study on the effectiveness of web-based EDC[14], found 
that the time for data entry was reduced by an amazing 75% compared with the 




entry errors were reduced by an astounding 100%. Even though fixed costs were 
higher for EDC, the variable costs of data entry were a quarter of that of PDC. 
The conclusion drawn was that the longer a study was conducted and the more 
CRFs were collected, the less the overall costs for EDC. The authors concluded 
that the main quantifiable benefits of EDC were reduced costs over time and 
lower error rate. Other tangible benefits mentioned were easier regulatory 
compliance and better control over data. 
In a trial of various EDC methods against PDC by Walther et al. in a field 
site in Gambia, various factors including data quality, time, cost, and clinical staff 
acceptability were evaluated.[2] With no data validation the error rates were 
found to be similar to those of PDC. EDC was quicker than PDC, especially as 
the staff became more familiar with the tools. Startup cost was again higher with 
EDC. However, as the study progressed and time to complete CRFs was 
reduced, EDC became more cost-effective. At a certain point the labor cost of 
PDC, followed by secondary data entry into a database, and finally data 
verification made PDC less cost-effective than EDC. Furthermore, EDC was 
widely accepted by field staff. Walther et al. conclude that EDC can be “a more 
time effective, … cost effective method”, yet stress the importance of good study 




Pawellek et al. found that being forced into a thorough study design 
process by the nature of using an EDC system was one of the main benefits. 
While their planning and design process was “more time-consuming” it was also 
a “great advantage” due to reduced error rates and higher quality data. The 
benefits of higher quality data, and therefore fewer data checks after the study 
completed, outweighed the longer implementation time. [15]  
Pavlović et al. performed a sophisticated business process analysis of the 
cost effectiveness of EDC versus PDC. The authors recognized the extreme 
inefficiency of the double entry method used in PDC, yet acknowledged 
technical requirements and uncertain cost of EDC. In all five separate testing 
scenarios there were clear cost savings with EDC and the main benefit was 
reduced data entry error rates. Identified disadvantages of EDC included the 
need to adjust to different organizational culture and regulatory compliance 
frameworks, as well as extended costs such as IT infrastructure that may not 
already be in place. [16] 
Two recent studies have reported similar advantages of EDC over PDC. 
[17] [18] Both observed lower total cost especially with longer-running studies 
and fewer errors when compared to PDC. Both studies also found data entry 




Staziaki, et al. compared data entry into Excel spreadsheets to EDC. 
Spreadsheets were seen to be potentially less expensive while eliminating double 
entry. EDC won on speed and data quality lending evidence that enforcing a 
study protocol is another major advantage of EDC.  
Researchers appreciate having greater control over the data. There are 
perceived benefits just by having data in hand and available. “Researcher-
controlled data services and secure data collection, storage and export is a 
universal need for any … research study.” [19] “Moreover, the large geographic 
areas associated with many research studies as well as the need to maintain the 
integrity of clinical trial data make [EDC] even more appealing.”[14] 
There is a large body of evidence showing that EDC is more effective than 
other data capture methods. Yet concerns over cost and technical demands 
persist. Often the specialized technical requirements such as setting up EDC 
software or lack of computing infrastructure are still barriers. Franklin et al. 
recognized that EDC solutions are difficult to set up and that this may limit 
small- and medium-scale studies without institutional support because many 
EDC solutions are designed for large-scale studies. Interestingly, Franklin et al. 
also concluded that research teams used to PDC are willing to work around 




Therefore more affordable EDC solutions designed for small and medium scale 
studies, may be a good fit for research teams with limited resources. Richesson 
and Andrews note that “while experimental expert-type systems have been 
developed with the idea of helping clinical investigators design their own trials, 
their scope is too limited to address the diverse issues that human experts 
handle.” [6]. In other words minimum viable functionality combined with 
flexibility is a better goal instead of the ability to handle every requirement 
imaginable. 
Study designers should realistically expect to need technical personnel, to 
some extent, to setup and manage EDC systems. This makes sense and parallels 
information systems everywhere. Any technical machinery needs an engineer or 
technician to keep it running smoothly.  
The benefits of EDC have been repeatedly demonstrated. However, it is 
challenging to develop an EDC system that is comprehensive enough to cover all 
clinical research use cases and at the same time simple enough to be fully 
managed by non-technical research staff. Therefore, neither a fully 
comprehensive feature set, nor complete elimination of programmer or technical 





2.2. Mobile Computing in Clinical Settings 
Our further aim is an EDC system that is fully functional on mobile 
devices, especially tablet and smartphones. Data capture using laptops and 
desktop PCs is usually limited to indoor stationary use. As Weber et al. pointed 
out, “limitations for this method of data collection have been the size of the 
computer (making it difficult to use in some field situations)”.[14] Tablets and 
phones offer a better mobile form platform.  
As early as a decade ago Morak et al. recognized that for mobile EDC, 
“the most challenging part is the user interface … and to synchronize.” [21] 
Despite implementing mEDC on now-obsolete phone hardware (e.g. a Nokia 
clamshell with no touchscreen), Morak et al. implemented mEDC with a custom 
client server architecture and concluded that their platform, although very 
limited in functionality, was “easy-to-use, intuitive and time-saving”. 
More recently Meyer et al. focused on the need for off-line functionality 
with later synchronization when using mEDC for conducting trials with home 
visits. [3] Instead of building a full system from the ground up, the team 
extended an existing clinical data management system to include remote client 
and synchronization functionality. They implemented a flexible EDC data 




complex part” of their implementation. Meyer et al. went into fine detail on their 
syncing algorithms, noting the complexity of supporting syncing with data 
dependencies, threaded concurrency, queuing requests, and conflict resolution. 
Pakhare et al. in a survey of phone-based mEDC in Africa found that 
mobile devices have the ability to enrich data with built in sensors such as 
cameras, microphones, and GPS sensors.[22] The resulting photographs, video 
clips, audio clips, and location data go beyond the capabilities of PDC or 
laptop/desktop EDC. Pakhare et al. also noted the low training requirement for 
use of mobile devices now that we live in an era when they are commonly used. 
On the other hand they noted limitations not encountered with PDC, such as 
maintaining a battery charge in remote locations, theft, malfunction, and reliance 
on network connectivity. 
Patel et al. found that mEDC on smartphones was key to their distributed, 
international study on smoking in vehicles. [23] Their previous study methods 
involved recruiting geographically dispersed observers using PDC to capture a 
body of data while observing occupants of moving vehicles. The team 
implemented mEDC with the goal of improving “time-consuming and 
fragmented manual methods”. The lead investigators created a data and 




developers to understand the development process and costs. In the end the 
team chose to work with student developers. Patel et al. discussed the 
challenging and lengthy process of development and highlighted the tangible 
and intangible costs of custom development. In the end the team completed a 
functional smartphone app that “may provide greater efficiency that traditional 
methods.” Not exactly a definitive conclusion, but the study noted the 
advantages seen with EDC in general: real-time access to data and improved 
data quality. [23] 
Van Heerden et al. directly compared mEDC on smartphones with PDC 
and replicated results of earlier EDC studies to confirm that error rates for mEDC 
methods comparably low to traditional EDC. Furthermore, like in earlier EDC 
studies, the benefits of mEDC over PDC are “magnified as the size and 
complexity of the study increases.” [24] This magnification of benefit is found 
because despite the higher startup costs of mEDC, the lower cost per participant 
becomes significant with larger, more complex studies. 
King et al. conducted a comparison of four mEDC software packages in 
order to replace their PDC methods in Malawi. [25] All fieldworkers preferred 
EDC to PDC for a variety of reasons. Among the notable subjective reasons to 




of papers and the prestige in the community the electronic device conveyed. The 
research team also considered the fieldworkers’ use of electronic devices to be a 
benefit in terms of the “opportunity of capacity building within communities.” 
Expected downsides were failures and theft of the equipment. However, these 
downsides were minimal and considered reasonable in the greater context. The 
team reiterated the emphasis we have seen before on the need for preparation 
and advance planning. The preparation phase took longer with EDC, yet once 
the studies were being conducted they ran smoothly. They conclude that mEDC 
is “not only viable, but desirable.” 
As an important counterpoint, Vélez et al. implemented mEDC in rural 
Ghana and encountered resistance among local healthcare workers. [26] The 
main complaint was that the workflow design was disruptive to the clinicians. 
Instead of designing a system that matched and integrated with the clinical 
workflow, the mEDC system disrupted the established clinical path. This 
resulted in resistance by the clinical staff. Two mobile phone models were used, a 
hardware keyboard model and a touchscreen model. The touchscreen was 
shown to have a lower error rate and greater user acceptance. Despite initial 
optimism from the clinical staff hopeful that the system would reduce an already 




problems” and one “usability catastrophe” in the design and implementation 
that became ultimately an unsustainable effort. The researchers conclude, 
“careful and thoughtful design is essential for successful implementation, 
scalability, and long-term sustainability” of an EDC project and emphasize the 
importance of early engagement with the clinical users of the system. In another 
case von Niederhäusern et al. encountered issues with a design that wasn’t rigid 
enough in enforcing the protocol for their mEDC system for clinical home visits. 
“[T]he mobile application was designed with the highest user flexibility and –
usability in mind in order to minimize user fatigue or dropout. This flexibility in 
data entry resulted in data points which were often ambiguous (e.g. 
inconsistencies in automatic time stamp versus time point indicated by caregiver, 
or typing errors for sample codes).”[27] Full reconciliation of the data would 
have entailed rigorous crosschecking of the data and perhaps repeated home 
visits. 
Several other mEDC systems have documented success in remote 
geographical areas with some familiar results: 
• A diagnostic and mEDC system “can greatly improve the delivery of 
quality health care in remote locations of low- and middle-income 




in a remote setting in Kenya is feasible.” [28] 
• “Despite challenges including prolonged setup times, the [mEDC system 
for a complex, four-armed, cluster-randomized, controlled trial in rural 
Nepal] met multiple data collection needs for users with varying levels of 
literacy and experience.” [29] 
• Because of the lack of existing research and technological infrastructure, 
“it may be possible for countries in Africa to implement leapfrog 
approaches that exploit the advantages of digital and mobile technologies, 
tools which have permeated and revolutionised many aspects of work and 
life around the world but have not yet been widely adopted for use in 
clinical trials.” [30] 
• In a randomized clinical trial conducted across 14 hospitals in China an 
mEDC system helped “doctors complete a phase IV pharmaceutical 
clinical trial and was feasible for management of this trial. Moreover, 
doctors expressed their willingness to use this tool for study 
implementation.” [31] Special emphasis was given to high user 
satisfaction and protocol enforcement features that benefited staff who 





With widespread acceptance and acknowledgement of the success of 
mEDC Eagleson et al. moved the discussion forward by focusing on ethics and 
the privacy and security issues related to electronic storage and transmission of 
protected health information (PHI). [32] The authors applied defensive strategies 
to the risk of external attacks as well as internal security layers to mitigate 
unnecessary access to PHI by authorized users. 
We conclude that mEDC is a highly successful strategy for managing 
clinical studies when properly designed and integrated with the clinical 
workflow. Areas of special concern when implementing mEDC should be 





3. ETHICS & GOVERNING REGULATIONS 
3.1. Ethics 
Systematized clinical research and drug trials began seriously in the 
twentieth century with the development of penicillin and other medical 
interventions. During this period research on human subjects was often 
conducted on vulnerable populations in prisons, orphanages, homes for the 
mentally disturbed, and other institutionally controlled groups without the 
explicit consent of the individual participants. The misguided, but common, 
justification was that these marginalized groups could be used for medical 
research as long as there was a benefit to the greater society.[7]  
The turning point for seriously considering ethics in research was the 
revelation of the experimentation Nazi doctors conducted on prisoners during 
World War II. The types of experiments conducted on prisoners without consent 
were horrific, including experiments with mustard gas, poisons, freezing 
temperatures, burns, high altitude, starvation, malaria and other contagious 
diseases, and deliberately inflicted wounds.[33] During the Nuremberg Trials 
following the war, the military tribunal developed a code of ethics by which to 
judge the accused. The Nuremberg Code established the “primacy of consent” 




The Nuremberg Code was limited in scope to judge defendants in the 
Nuremberg Trials, yet it led to further development of global ethical guidelines. 
In 1964 the World Medical Association published the first edition of the 
Declaration of Helsinki[34] and international consensus document and the basis 
for many future national guidelines. The Declaration of Helsinki established 
basic principles of ethical research on human subjects and importantly 
differentiated ethical treatment during clinical care from non-therapeutic 
research. 
The Declaration of Helsinki was and remains an unenforced consensus 
document and no legal code for human subject research had yet been 
established. Meanwhile questionable research practices continued. In 1966 Dr. 
Henry Beecher pursued the issue in a landmark paper “Ethics and Clinical 
Research”[35] Dr. Beecher cited many contemporary examples of published 
studies conducted by well-respected research institutions where consent of 
human subjects was not requested, known effective treatments were withheld, or 
risky procedures were performed on healthy individuals. These studies resulted 
in serious side effects including death. In analyzing the frequency of ethical 
breaches Beecher noted the ease with which he identified questionable ethical 




likely ethical violations. These seventeen “easily increased to 50” that led to “186 
further likely examples.” Beecher highlighted two primary components to an 
ethical approach to clinical research. The first was informed consent. “The 
statement that consent has been obtained has little meaning unless the subject or 
his guardian is capable of understanding what is to be undertaken and unless all 
hazards are made clear.” The second important factor he added is the “safeguard 
provided by the presence of an intelligent, informed, conscientious, 
compassionate, responsible investigator.” He found both of these factors lacking 
in the ethical climate at the time. 
Beecher’s paper brought wide attention to an ethical crisis within the 
United States research community. Other revelations at the time such as of the 
hepatitis B studies at Willowbrook and the Tuskegee syphilis studies drew 
additional public scrutiny.[7] This widespread, public attention to ethics in 
research led to the formation of the governmental National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research. This 
commission produced the Belmont Report in 1979. The Belmont Report[36] was 
the first of its kind in the United States, a groundbreaking, government-
sponsored guidelines document for ethical principles for research involving 




research, basic ethical principles for research, and specific guidelines for 
informed consent, selection of subjects, and assessment of risk.  
The Nuremberg Code, Declaration of Helsinki, and The Belmont Report 
together became the basis for regulations developed beginning in the 1980s that 
govern the protection of human research subjects internationally.  
3.2. United States Regulations 
3.2.1. Protection of Human Subjects 
The United States regulations that govern the protection of human 
research subjects are referred to as “The Common Rule”. The Common Rule is 
codified in Title 45 of the Code of Federal Regulations (CFR) Part 46 [37], referred 
to as 45 CFR Part 46. This regulation provides rules for Institutional Review 
Boards (IRBs), informed consent, and special protections for vulnerable groups.  
IRBs are governing bodies formed by the institution sponsoring the 
research to oversee the protocols and conduct of a study involving human 
subjects. IRB rules detail the role of the IRB in oversight, how to select the 
membership of an IRB, and when expedited review procedures may and may 
not be used.  
Informed consent is strictly required when performing research on human 




obtaining] legally effective informed consent”.[37] Informed consent involves 
explaining to the research subject the following details at a minimum: 
1. Purposes of the research,  
2. Duration of participation,  
3. Procedures to be followed,  
4. Foreseeable risks,  
5. Benefits to themselves or others,  
6. Alternative treatments,  
7. Extent of confidentiality of their records,  
8. Compensation or treatment available for research-related injury,  
9. Whom to contact for more information about the research, 
10. Their rights as participants, and 
11. Participants’ right to withdraw from the research study at any time. 
Additional requirements apply under special circumstances or increased 
risk. The informed consent procedures must be documented in the study 
protocol and approved by the IRB. 
The Common Rule also codifies special protections for vulnerable groups 
such as pregnant women, fetuses, newborns, children, and prisoners. For 




minimize risk and hold the prospect of direct benefit to the fetus or newborn. 
Both the mother and the father must grant consent – as long as both are 
available. When children – defined as “persons who have not attained the legal 
age of consent” – are to be the subject of research, assent by the child – defined as 
“affirmative agreement to participate” – is required in addition to consent by the 
parent or guardian. When prisoners are to be involved in research, the majority 
of the IRB is to “have no association with the prison” and at least one member of 
the IRB must himself or herself be a prisoner.  
The Common Rule was revised in 2017 to provide greater protections for 
subjects while streamlining the compliance process for researchers. [38] The 
revised rules allow consent forms to be more concise and to contain more easily 
understandable language. Consent forms should now be organized for clear 
understanding for participants above legal protection of the researcher. The new 
standard is “reasonableness” instead of “comprehensiveness”. IRBs will be 
allowed to spend less time overseeing low-risk studies in order to focus more on 
high-risk studies. Researchers will be allowed to request “broad consent” in 
order to use PHI or identifiable bio-specimens for future, undetermined research. 
Finally, the updated rules allow for single-IRB oversight for multi-institutional 




upon researchers while maintaining protections for human subjects. 
Other parts of the Code of Federal Regulations expand rules for informed 
consent, additional safeguards, IRBs, new drugs, device exemptions, and 
research conducted outside the United States. [39-44] Table 1 details these parts 
of the CFR.  
 
U.S. Regulation Covered Topics 
Title 45 CFR Part 46 
IRBs, informed consent, additional protections for 
vulnerable groups 
Title 21 CFR Part 50 Informed consent, additional safeguards 
Title 21 CFR Part 56 IRBs 
Title 21 CFR Part 312 Investigational new drugs 
Title 21 CFR Part 812 Investigational device exemptions 
Title 22 CFR Part 225 U.S. funded research conducted outside the U.S. 
Table 1. U.S. regulations for protection of human research subjects 
 
3.2.2. Electronic Records and Electronic Signatures 
The U.S. Code of Federal Regulations Title 21 Part 11[45] known as 21 CFR 
Part 11, or just Part 11, states that electronic records that meet specific 




Department of Health and Human Services has stated that the scope of records 
that are covered by 21 CRF Part 11 is to be interpreted narrowly. [46] Within that 
narrow interpretation the two categories of information include electronic 
signatures, when they are used in lieu of physical signatures, and Protected 
Health Information (PHI). The Health Information Portability and Accountability 
Act (HIPAA), 21 CFR Parts 160-164, further governs the definition and 
management of PHI.  
 
U.S. Regulation Covered Topics 
Title 21 CFR Part 11 Electronic records and signatures 
Title 45 CFR Part 160 HIPAA General Administrative Requirements 
Title 45 CFR Part 162 HIPAA Administrative Requirements 
Title 45 CFR Part 164 HIPAA Security and privacy of PHI 
Table 2. U.S. regulations for electronic records and healthcare data 
 
Electronic signatures must be based on unique biometrics, or on two 
identification components such as a user account name and password. Electronic 
signatures must be linked to their respective electronic records in a way that they 




means.” Controls must be in place to de-authorize lost or stolen identification 
tokens, as well as to detect attempts of unauthorized use of identification tokens. 
Research data when combined or crossed with clinical treatment will be 
governed by HIPAA regulations that have privacy and security requirements. 
Complete coverage of HIPAA regulations is out of the scope of this work. 
However, 45 CFR Part 164 [47] creates specific requirements for data 
management, encryption, privacy, and disclosure when breaches occur. 
3.3. International Regulations 
Research that is conducted outside the United States that is funded by the 
U.S. Federal Government agencies is regulated by 22 CFR Part 225 [48] in 
addition to regulations in the local jurisdictions. Many countries have developed 
their own regulations for protection of human subjects in research. Many are 





4. CONNEDCT ARCHITECTURE 
4.1. Architectural Goals 
The primary goals of the ConnEDCt architecture are mobility, flexible 
support for complex study protocols, and reuse. Some features like data security 
and privacy are required for any EDC system as per regulations discussed in 
chapter 3. Beyond these core requirements, ConnEDCt focuses on mobility and 
support for complex protocols as differentiators from other EDC platforms. 
ConnEDCt provides sophisticated protocol support features; intuitive user-
interfaces with low training requirements; offline operation; and data syncing. 
ConnEDCt is built with a mobile-first philosophy with a focus on tablet 
data-entry. Off-line operation and a touch-based, mobile user interface (UI) are 
fundamental to the design and architecture. Although ConnEDCt is also suitable 
for data capture on a desktop or laptop PC, the user interface is optimized for 
data capture on mobile devices. iPads are the primary devices of the intended 
audience. ConnEDCt is fully functional off-line with no required connection to a 
central data repository (CDR) except when syncing or receiving app updates. 
Local file storage allows for off-line operation and faster program 
responsiveness, since, unlike with web-based apps, the users never wait for data 




One of the main challenges in supporting clinical studies has been 
creating a re-usable system that can be implemented for the most part by the 
research team without help from software programmers. Like Harris, “we 
realized early in the project that the critical factor for success would lie in 
creating a simple workflow methodology allowing research teams to 
autonomously develop study-related metadata in an efficient manner.”[19] 
Although a programmer is still required for implementation of a new study, a 
concise procedure makes programmer involvement as minimal and efficient as 
possible. Future development goals that will be discussed in Chapter 6 include 
further reduction of programmer effort in the implementation of new studies. 
Most likely some programmer effort will always be required to implement novel 
features or assist with complex algorithms. 
Richesson & Andrews noted that “special problems still arise that only 
custom software development can solve.”[6] So far we have implemented several 
independent clinical studies with ConnEDCt. These will be described in detail in 
Chapter 5. Although developer support was required in all cases, in three out of 
six studies we implemented the study protocol designs with the standard feature 
set, without custom programming. In the other cases custom programming was 




novel but important features were then adopted into the platform. Many features 
such as dynamically generated CRFs, randomized groups, and an agenda view 
were added when a study required them and were implemented as platform 
features. Each implementation has been built on the previous experience so that 
most new features were integrated into the platform for re-use with future 
studies. 
4.2. System Components 
ConnEDCt consists of a distributed database built with the Claris 
FileMaker platform[49] plus a couple of 3rd party modules that are integrated for 
discrete functions. FileMaker is a commercial app-development platform by 
Claris International Inc., a subsidiary of Apple Inc. FileMaker combines a rapid 
development environment with native compatibility for personal computers 
(PCs) and mobile computing devices. The FileMaker platform includes a 
proprietary database engine, an integrated development environment (IDE), a 
server component, native clients for Windows and MacOS PCs, and a native 
mobile client for iOS. This full suite of built-in capabilities provides advantages 




4.3. Database Schema 
Figure 4.1 shows ConnEDCt’s entity relationship diagram (ERD) and the 
structure of the database. The three entities FormType, VisitType, and 
FormSchedule establish the basic study schema. The FormType entity represents 
CRFs; the VisitType entity represents defined participant encounters; and the 
FormSchedule join entity represents the schedule of CRFs used in each 
encounter. Other aspects of the study protocol such as eligibility criteria and 
coded list values are represented by respective database entities. 
For each study implementation CRF variables are hard-coded in new 
“CRF_” database tables that correspond to the CRFs defined in the Form table. 
An arguably better schema design would be to abstract the CRF variables in a 
Variable table so the CRF definition could be accomplished by an end-user. 
There were various reasons for taking the direction of the current database 
model, including limitations of time, resources, and capabilities of FileMaker. An 
alternate database schema that allows for user-defined schema is discussed in 





Figure 4.1. Conceptual entity relationship diagram (ERD) of ConnEDCt 
Aspects of features such as device registration, eligibility, scheduling, e-
signatures, and randomization are supported in the database schema with 
relationships and attribute values. Appendix A shows table attributes for the 
entities discussed below. 
The Device table entity stores records for every device that was used to 
sign into a ConnEDCt study. Information stored for each device includes the 




details discussed in section 4.5.4, as well as device attributes and hardware 
capabilities.  
Eligibility criteria formulae are stored in the EligibilityCriterion table with 
relationships to the specific visit and form that the formulae references. Instances 
for participant eligibility status are stored in the PartEligibilityCriterion table 
with a relationship to the EligibilityCriterion table. 
Participant encounters and assignments of CRFs to encounters are defined 
in the VisitType and FormSchedule tables. Visit attributes include the ordering of 
visits, schedule in days from start of the study, whether to automatically create 
the next visit when scheduling–or stop the scheduling procedure, and whether 
eligibility is required before creating the visit in the schedule. Randomization 
attributes that affect CRF scheduling – discussed in section 4.5.7 – are also stored 
in the FormSchedule table. 
The PartEventForm table manages metadata associated with the CRF 
including completion and sync statuses, e-signatures, and relationships to the 
participant encounter and form record the CRF is associated with. 
Finally, study randomization data is stored in the StudyGroup and 
Randomization tables. The StudyGroup table has strict access controls to enforce 




assigned when a randomization record is assigned to a participant. The 
randomization record maintains the order of the list, the study group, and 
whether a record has been assigned. The randomization record also contains the 
visit number to apply the serial sampled CRFs – see section 4.5.7. Because 
randomization may be centralized or federated, the randomization record also 
stored the device ID that has authority to assign it. 
The database schema manages all the persistent information on the study 
schema design. Whenever special requirements arise for a new study protocol 
feature the priority is to adopt the change in the study schema to allow for 
framework adoption. 
4.4. Data Lifecycle and Data Quality 
4.4.1. Data Security and Privacy 
HIPAA regulations require electronic systems to “ensure the 
confidentiality, integrity, and availability” of PHI.[47] These terms have specific 
definitions within the code and explicitly require encryption and audit logging, 
while implicitly requiring business continuity and contingency plans. Encryption 
in ConnEDCt takes two forms: file encryption, also known as encryption at rest; 
and encryption in transit, in other words encrypting the online data traffic 




the CDR and on client devices in order to enable offline functionality. These files 
are encrypted with the AES-256 encryption algorithm using native FileMaker file 
encryption features.[50] Data in transit between the ConnEDCt CDR and client 
devices is encrypted using transport layer security (TLS) and third-party SSL 
certificates applying the SHA-256 algorithm with RSA (Rivest-Shamir-Adleman) 
encryption. 
User account access is controlled with usernames and passwords with 
role-based access control. Research Associates collecting data in the field have 
different access requirements than statisticians analyzing data. RAs typically 
have access to capture a full dataset – or segmented data, if they focus only on 
particular subsets of study data – whereas statisticians are prohibited from access 
to identity data.[6] Data Managers have limited ability to make corrections to 
captured data. 
4.4.2. Syncing 
Two of the great benefits of EDC are real time data analysis and data 
security. A system that operates off-line must store data locally. However, local 
data storage leaves the data isolated and vulnerable to loss. Full data security 
therefore requires that data must be transmitted to a CDR. There are many 




tracks changes only. Syncing is a complicated programmatic problem involving 
comparison of changes, time zone corrections, conflict resolution, error 
correction among other challenges. ConnEDCt integrates a commercial syncing 
engine in order to achieve the best possible results. We tested several commercial 
solutions before settling on 360Works MirrorSync[51]. MirrorSync provides 
relatively simple integration with our FileMaker software platform and reliable 
operation over even poor network conditions. In addition 360Works has released 
several MirrorSync upgrades over the last few years that have improved 
performance.  
We use a “most recent change wins” configuration and syncing is as 
simple as tapping a button in the interface. Sync time depends on the amount of 
data changes to be uploaded and downloaded.  
4.4.3. Audit Logging 
Audit logging is a feature that is built into many relational database 
management systems (RDBMS), but not FileMaker. Audit Logging is another 
challenging feature to be implemented from scratch with many nuances to be 
considered. Therefore we implemented audit logging with an add-on module, 
AuditLogPro 2.0[52] by 1-More-Thing. Changes are collected during data entry 




log in only one direction – from devices to the CDR, so that it is not sent from the 
CDR to devices. Aside from maintaining data security by not storing the full log 
on every device, the log also becomes quite large, so syncing in one direction is a 
more efficient use of the network. 
4.4.4. Form Validation 
Form validation is performed as a pre-processing step prior to signing a 
CRF. Validation is accomplished in one of two ways. Specific validation checks 
can be programmed for each variable in each CRF, or by default every variable 
shown on the CRF can be checked to verify it has a non-empty value. These 
validation rules are a part of the custom programming step of an 
implementation. Validation rules should be documented in the study design 
stage. 
4.4.5. Form Signing 
Electronic signatures ensure the authenticity of the captured data.[45] An 
RA must verify their identity by account name and password when they sign 
each form after having completed it. These electronic signatures capture the 
identity of the RA, the timestamp, and GPS coordinates (if available on the 




data manager can override this. Signed CRFs are marked as complete. When all 
forms in a visit are signed and completed, the participant visit is marked as 
complete.  
4.4.6. Data Export 
Exported data is used for deeper statistical analysis than can be performed 
in a typical RDBMS. Two types of data export can be run on demand from 
ConnEDCt: a full, de-identified dataset, and a separate export of participant 
identity records. Both exports result in a collection of Microsoft Excel files. The 
de-identified dataset includes one Excel file for each CRF that identifies the 
participant only by study ID and also includes metadata for visit number, date, 
etc. This export also includes a data file of coded lists. After experimenting with 
different file formats, Excel has turned out to be the most compatible option. 
4.5. Functional Components 
4.5.1. Case Report Forms 
Case report forms are implemented using the FileMaker IDE. One table 
represents each CRF with a series of standard fields, such as database keys, and 
fields for data entry. It’s worth mentioning that, in this intersection of disciplines, 




for storing one piece of data. 
FileMaker supports data types of text, number, date, time, timestamp, and 
container for storage of binary objects. FileMaker’s “Layout Mode” environment 
is used for designing the data entry form. FileMaker-native field entry modalities 
include: free text, numeric, pop-up menu, date picker, and radio buttons. Other 
entry modalities can be provided with custom programming. Pop-up menus and 
radio buttons support coded lists so that the end user may see natural language 
choices, while the database stores numeric codes that enforce consistency and 
better data analysis. 
4.5.2. Coded List Management 
Coded values are essential for facilitating statistical analysis as well as 
optimizing data management.[19] A coded list item is represented by a text 
description with meaning in natural language and a stored code – usually 
numeric – that is more useful for data analysis. Having a code married to a 
natural language description also allows the description to be revised – fixing 
typos, adding precision language and translations – without affecting the coded 
value.  
Coded lists can be used with pop-up menus, radio buttons, and other 




the users, yet the database should store a coded value. The end user chooses the 
text label value (e.g. “No” or “Yes”), whereas the database stores the coded value 
(e.g. 0, or 1). Radio buttons are useful for shorter lists; likewise, longer lists of 
coded values can be presented as pop-up menus. Multiple-choice options can be 
represented as checkboxes. Coded lists are exposed to data managers for 
customization as shown in Figure 4.2 and applied to fields in the FileMaker IDE.  
 





4.5.3. CRF Scheduling 
The CRF schedule allows visits to be scheduled in advance and 
appropriate CRFs to be presented to RAs for data capture. It is one of the most 
basic elements of support for the study schema. Figure 4.3 shows the form 
collection protocol design document for the Biofortified Pearl Millet Trial[53], a 
clinical trial that employed ConnEDCt as its data capture solution. CRFs are 
shown down the vertical axis and participant visits are defined across the 
horizontal axis. The key indicates that some CRFs depend upon predicate 
conditions. ConnEDCt supports the conditionality of CRFs based on eligibility, 
randomized serial sampling, randomized subsets, and the values of specific 
variables in other CRFs. Based on these conditions CRFs may or may not be 






Figure 4.3. Form collection protocol design document for the Biofortified Pearl Millet 
Trial[53] 
 
ConnEDCt provides an interface for study designers to translate the study 
schema design into the ConnEDCt study schema. CRFs are first defined by name 
in the form list. Figure 4.4 shows the CRF Scheduler interface for the Midline 1 
visit of the Biofortified Pearl Millet Trial. This interface includes details for 
scheduling as well as inclusion in the randomized CRF serial sampling and 











4.5.4. Study IDs 
Working offline with multiple devices poses a challenge for serializing 
study IDs. It is given that every participant must be assigned a unique study ID 
for study integrity, as well as working with de-identified data. These IDs must be 
assigned upon the first interview with a participant and must be unique. Since 
participant records are created on devices that may not be connected to the CDR, 
the devices must be able to assign unique IDs despite not having this centralized 
coordination. Universally unique identifiers (UUIDs), while suitable for database 
primary keys, are too cumbersome to be practical as study IDs. Therefore a 
federated model of ID assignment must be used so that each device can assign a 
unique ID independently. The study ID is constructed using an identifier for the 
device followed by a participant number from a list maintained independently 
for each device. 
To begin, every individual data capture device used for the study is 
registered with a unique, serialized identifier (e.g. 1, 2, 3, etc.). This involves 
capturing a persistent device ID, a unique hardware code that identifies the 
device, and associating it with a record in the Device table. Each record in the 
Device table matches a device registered with the study. The Device table stores 




participant is created, the study ID is constructed from the serialized device 
number and the next participant number on that device. Then the value in 
NextParticipantNumber is incremented. For the first participant created on the 
first registered device, the study ID may be “1.1001”. The number of digits in the 
participant number segment is determined by the estimated enrollment in the 
study. Other segments may be added to differentiate multiple studies by a PI or 
institution and to indicate the study group or trial arm. An example of a full 
study ID would be “PM.01.1001-B” using the formula “[study code].[device 
number].[participant number]-[study group]”. 
4.5.5. Consent Forms 
Consent forms are implemented like any CRF plus including details for 
recording the method of consent plus optional capture of hand-written 
signatures. However, because participants are not authenticated users of 
ConnEDCt, their electronic signatures are not considered valid.[45] Therefore the 
consent record is recorded separately. Chapter 5 explores the various methods 
used for maintaining records of informed consent, including video capture of the 
informed consent interview, and paper-based capture of signatures or 
thumbprints. In all cases the status of consent is recorded for evaluating 




4.5.6. Eligibility Controller 
Automating eligibility as another protocol support feature lifts the burden 
of managing eligibility from the RAs and makes the interview and recruitment 
process easier. With PDC eligibility requirements were often consolidated on a 
single eligibility CRF. However, consolidation of unrelated questions could 
create an awkward workflow, for example mixing physician exam details with 
anthropometry, or lab results. This information is captured by different clinical 
staff or, in the case of lab results, take time to process. Automating the eligibility 
process, on the other hand, allows eligibility questions to be placed on relevant 
CRFs where they belong in the workflow.  
The eligibility algorithm is defined in the EligibilityCriterion table as a 
series of formulae referencing one or more variables in a CRF. Any CRF, and the 
study as a whole, can have unlimited eligibility formulae. When a participant is 
created, records are instantiated in the ParticipantEligibilityCriterion join table 
for each EligibilityCriterion record. The eligibility controller runs each time an 
RA signs a CRF. At that moment any eligibility criteria referencing that CRF are 
evaluated and ConnEDCt updates the participant’s eligibility status. Figures 4.4-
4.6 show an eligibility algorithm and the three statuses: incomplete, ineligible, 




criterion is negative (i.e. ineligible), or all criteria are positive (i.e. eligible). 
 
 
Figure 4.4. Incomplete eligibility status 
 
 
Figure 4.5. Ineligible status 
 
 
Figure 4.6. Eligible status 
 
4.5.7. Randomization Controller 
The randomization controller handles three randomization functions: 
assignment to a study group, CRF serial sampling, and assignment to a 




protocol requirements and workflow considerations. ConnEDCt can import a 
randomization table that includes a study group code, a serialized CRF value, 
and a CRF subset flag. The StudyGroup table also stores the meaning behind the 
study group codes. The StudyGroup table is confidential and access is controlled 
in order to maintain blinding. 
After eligibility is evaluated and the participant is enrolled in the study, 
they are assigned a randomization key from the randomization table and the 
randomized study group code is appended to the study ID. The key to the 
randomization record is added to the participant record for referencing other 
randomized parameters. The randomization record is marked as used and 
cannot be assigned again. 
In addition to the study group ConnEDCt supports randomized CRF 
serial sampling and randomized participant subsets. The form collection protocol 
in Figure 4.3 shows the use of randomized CRF serial sampling. The key shows a 
pattern indicating “req. random (once)”. This key is assigned to four CRFs over 
eight visits. The result is that each of these CRFs will be assigned on one of the 
eight visits depending on the randomized value in the SerialSampleNumber 
attribute of the Randomization record assigned to that participant. The biological 




by the randomized serial number value. 
The workflow may demand that the study group is known immediately 
upon participant eligibility, if, for example, a treatment is administered at this 
visit. In this case a subset of the complete randomization table – maintaining 
block cohesion – can be loaded onto each device and randomization can be 
performed with decentralization of the system. An estimate must be made of the 
maximum recruitment numbers and the randomization series is divided among 
the devices that will be used for recruitment. Since each device will not recruit an 
equal number of participants a margin of error of extra randomization records 
must be added to each device.  
4.6. Study Protocol Implementation 
The implementation in ConnEDCt of each new study protocol is a 
collaborative effort between the research teams and ConnEDCt developers. Each 
implementation has provided the opportunity for more features to be added to 
the platform and for existing features to be re-used. Developer effort decreases 
with each implementation. 
Two design documents are key to define the study protocol and 
standardize it for implementation. The form collection protocol design document 




The data dictionary document provides the granular details of each CRF 
including variable names, data types, variable labels, descriptive text and coded 
lists for radio buttons, checkboxes, and drop-down menus. A well-defined data 
dictionary facilitates efficient communication among team members and reduces 
ambiguity when implementing data structures. Together these two documents 
cover most of the specifications. However, implementation is always an iterative 
process that involves revisions to these documents as well to ConnEDCt before 
participant recruitment begins. Invariably some refinements continue even after 
recruitment begins. 
The Form Collection Protocol and Data Dictionary combined with an 
integration procedure allow fast implementation of the study schema in 
ConnEDCt. The implementation procedure follows these steps:  
1. Create a new blank instance of the ConnEDCt system. 
2. Create records for CRFs and participant encounters. 
3. Create database tables for each CRF. 
4. Create coded lists or import from the data dictionary. 
5. Write validation scripts. 
6. Add the eligibility criteria. 




Once the implementation steps are complete, the system is ready for 
testing by the research team to verify workflow and all other details. Notes are 
taken and revisions made until the system is approved for deployment. 
4.7. Deployment and Updates 
Deployment happens in two stages. First the ConnEDCt files are loaded 
on a server and then they are deployed to client devices. The server is running 
the FileMaker Server and MirrorSync services. This can be on any server with 
reliable high-performing internet service including on premise servers or cloud 
servers. Several commercial hosting providers offer this specific FileMaker and 
MirrorSync configuration or it can be built to spec. 
Once the files are hosted the sync configuration is implemented in the 
MirrorSync console. Once sync is implemented the hosted files and client files 
are keyed to one another. MirrorSync provides a download link for client-side 
deployment. Since ConnEDCt runs within the FileMaker Go client application on 
iOS and FileMaker Pro on Mac and Windows, client devices must have one of 
these apps installed. Then deployment consists of installing an empty audit log 
file and then clicking the MirrorSync download link for the main ConnEDCt file.  
Many revisions to the study protocol – such as changes to protocol 




the file. They will be delivered to the clients upon the next sync. Changes to 
database schema-related features such as variables and validation will require 
redeploying a new ConnEDCt file. This is a two-step procedure of syncing data 
to the server and then downloading a new ConnEDCt file with the MirrorSync 
download link that will replace the old file. The audit log file should never 
change during the course of a study so should only ever need to be deployed 
once.  
4.8. Data Capture Workflow 
ConnEDCt’s data capture workflow follows some common clinical 
interview patterns including informed consent interview, eligibility assessment, 
and one or more clinical encounters. We have made assumptions that many 
patterns are common to the majority of clinical studies. Elements including 
informed consent, CRFs, participant encounters, and eligibility criteria exist in 
most, if not all, clinical studies. Some patterns such as randomized study groups 
are specific only to particular study designs. The data capture workflow is 
designed around these assumptions. 
The typical interview session begins with the RA opening the ConnEDCt 
app on an iPad. After receiving the encryption key and user authentication, 




Participant List interface features navigation buttons to switch between the 
participant list and the agenda view; buttons for ‘new participant,’ ‘sync to 
cloud,’ and ‘exit’; and a field to search for participants by name or study ID. The 
list of participants is grouped by eligibility status.  
When creating a new participant, minimal information is captured, 
usually just the participant’s name, and, if a minor, the guardian’s name. 
ConnEDCt then generates a study ID; the initial visit or visits, depending on the 
study schema; and the CRFs associated with those visits. The new participant 















Once a participant is enrolled – eligibility questions and consent are 
complete and randomization is applied, if necessary – the RA will schedule the 
remaining visits for the study. ConnEDCt then generates the visit and form 
records following the study schema. CRFs dependent upon predicate criteria will 
be created as needed when signing a form containing the predicate variables. 
Figures 4.9 and 4.10 show the visit list and form list interfaces. 
RAs keep track of follow-up appointments with the agenda view, shown 
in Figure 4.11. The agenda view allows the RA to see all visits scheduled for a 
specific day or an entire week, as well as export the list if needed to hand off to a 
receptionist. The RA is able to step forward and backward by date to view the 
past, present, and future appointments. 
An RA will create forms to capture unscheduled events such as dropouts, 
adverse events, and special notes from the event list interface with the ‘new 
event’ button. These ad hoc, special forms are essentially single form events and 
are listed within the events list. Using these form generation and data 


























5. CASE STUDIES 
Six study protocols have been implemented with ConnEDCt. Five of those 
studies have moved ahead with enrollment and are continuing to use ConnEDCt 
in the field for primary data capture or have completed the investigatory phase 
of the study. These five active or completed studies are: Pearl Millet 
Biofortification (PMB), FeverPhone, Periconceptional Surveillance in India (PSI), 
Multi-biofortified Food Crops (MBFC), and Environmental Determinants of 
KSHV in Uganda (EDKU). Figure 5.1 shows the geographic distribution and 
relative participant volumes of the active and completed studies. 
 
Figure 5.1 The five studies that have used or are using ConnEDCt for data capture by 






These studies have widely varying protocols and levels of complexity in 
their schemas, and the five studies that have gone ahead with data capture have 
widely varying volumes of data. This chapter will address specific complexities 
for each case study. Figure 5.2 shows the relative complexity of the schemas. 
FeverPhone shows a lower level of complexity with only three visits and a total 
of 18 instances of scheduled CRFs, whereas MBFC has 11 visits and almost ten 
times as many instances of scheduled CRFs.  
 
Figure 5.2 The schema metrics of the six case studies. 
 
The static schema of scheduled visits for a study does not demonstrate the 
full complexity of the data capture protocol. Unscheduled CRFs can represent a 




though the numbers of CRFs and scheduled CRF instances are roughly the same 
for the PSI study (the yellow and green bars in Figure 5.2), Figure 5.3, data 
capture metrics, shows the total number of signed CRFs (the green bars) to be 
highly differentiated from the actual participant encounters (the yellow bars). 
This is due to a high number of dynamically generated CRFs based on predicate 
variables. Additional CRFs were dynamically scheduled based on participants’ 
responses. Dynamically scheduled CRFs are a significant part of this protocol. 
We will look at other specifics of the case studies in the following sections. 
Detailed schema and data capture metrics are shown in the appendixes. 
 





5.1. Vitamin D Supplementation Among TB Patients in South India 
The genesis of ConnEDCt was the need to have an EDC tool for an RCT 
that would operate in rural settings with only occasional, slow access to the 
Internet. The VDTB trial was designed “to assess how vitamin D 
supplementation affects immunity”[54] in a participant pool of 200 tuberculosis-
positive adults in southern India. The trial was expected to require a combination 
of home visits and clinic visits with a staff of trained RAs conducting the data 
capture on iPads. The requirement for home visits in rural India necessitated 
disconnected data capture operations.  
This trial was our pilot project and the first implementation of ConnEDCt 
and was the initial basis of the framework. The research team developed the 
initial CRF designs within the FileMaker IDE. Meanwhile, framework 
development proceeded, including interface designs, navigation, data integrity 
assurance, electronic signatures, syncing, consent, eligibility, coded lists, and 
scheduling methodologies. A great deal of adjustment to the organization of 
variables and CRFs was made during the design process. This work included 
consolidating CRFs, moving variables from one CRF to another, and adding or 
eliminating variables. These adjustments were made to expand or limit the scope 




capture data. Because these adjustments were made after the CRFs had been 
implemented within ConnEDCt, they required a large amount of developer 
effort and iterative review by the research team. So early on we learned of the 
need for greater autonomy by the research team in the design process. 
This trial was put on hold and never proceeded to recruitment. However, 
the development process revealed to us several areas in EDC, such as eligibility 
determination and complex scheduling, that would be beneficial to adopt in the 
framework. 
5.2. Pearl Millet Biofortification Trial in Mumbai 
The PMB trial was the first full implementation of ConnEDCt. This RCT in 
Mumbai, India investigated “the effect of the consumption of foods prepared 
with iron- and zinc-biofortified pearl millet (FeZn-PM) by children on 
biomarkers of iron and zinc status, growth, and immune function.”[53, 55] We 
added a number of enhancements to the ConnEDCt framework to support this 
trial. Feature development focused on offline operation and randomization. 
Again the CRF design process was highly iterative with extensive collaboration 
between the study design team and the engineering team.  
Newly developed features to support offline operation included syncing, 




algorithm. To minimize the creation of irrelevant records and optimize syncing 
efficiency, RAs manually scheduled future visits after eligibility is satisfied. New 
features to support randomization included randomization of blinded study 
groups and randomized CRF serialization. Randomization began with a 
federated model and adjusted to a centralized model. Both modes are still 
supported in the framework.  
At the end of the implementation process, the trial began with a three-
month pilot project that allowed the team to refine the clinical workflow and 
extensively test the syncing functionality. The initial syncing methodology 
proved to be unreliable in rural India where Wi-Fi and mobile internet was slow, 
with high latency, and often-dropped connections. Early on we changed to the 
MirrorSync module that performed faster and recovered from dropped 
connections more reliably. Even after switching to MirrorSync, syncing was 
challenging for several months until more reliable internet connectivity was 
established. Frequently dropped connections resulted in incomplete syncing and 
created syncing conflicts that required manual resolution. Manual resolution of 
syncing conflicts required both a deep understanding of the syncing concept and 
a firm grasp of the data model. Frequently consultation between an engineer and 




Participant recruitment began in March of 2017 and data capture was 
completed in August 2018. We encountered a few issues during the year and half 
of data capture. Because RAs scheduled visits manually, it was possible for 
duplicate visits to be created on different iPads by different RAs. After syncing, 
the duplicate visits appeared on all devices. It required careful attention by the 
DM to mark and delete duplicates and repeat the sync to remove the duplicates 
from all devices. We mitigated this issue in future studies by revising the 
framework to automate scheduling. 
The study design team extensively planned and tested the CRFs and the 
study protocol throughout implementation and the pilot. The DM and local RA 
team tested many iterations of CRF designs and the newly added platform 
features. Despite this extensive testing, additional changes were required to 
CRFs after recruitment had begun. In some cases the order of questions on CRFs 
was modified to better match the clinical workflow. In other cases a few variables 
were added to CRFs. One change was made to correct a flaw in the eligibility 
algorithm. The requirements for changes despite the heavy testing pre-launch 
further affirmed the need for investigator-defined study schema and a data 





The ongoing FeverPhone study in Ecuador aims to support the research 
and development of a point of care diagnostic device for febrile illnesses. [56] 
The implementation of the FeverPhone study required very few programmatic 
additions to ConnEDCt. It was, therefore, a good model for developing an 
efficient implementation procedure. 
Some modifications were made specifically to support the FeverPhone 
study protocol. The interface was localized in the Spanish language to support 
the local research staff in Ecuador. This localization was hard-coded. Since 
ConnEDCt is used internationally, language localization is a candidate for future 
development. The protocol also called for separate consent or assent forms based 
on the age of the participant.[57] Adult participants receive a consent form, 
whereas minors require a parental consent form and a participant assent form. 
FeverPhone required very little modification or support post-launch. Participant 
recruitment began in June of 2017 and is continuing indefinitely. The timing of 
data capture focuses on the seasonality of febrile illnesses in the region.  
5.4. Periconceptional Surveillance in India 
Several severe, neurological birth defects, such as spina bifida, are linked 




provided pre-intervention biomarker data to aid the development of a future, 
randomized, controlled efficacy trial.  
PSI has been the most challenging implementation of ConnEDCt due to 
the large number of CRFs and the complex protocol that went through extensive 
revisions and refinements during implementation. Although ConnEDCt’s 
customizable framework model was well suited for the study, the design process 
further reinforced the need for more of the protocol implementation to be 
independent of developer involvement. ConnEDCt became a useful tool for the 
research team to experiment and clarify issues with the study protocol. Previous 
studies with simpler protocols required far less programmer effort and fewer 
revisions. It is understandable that a complex protocol is more difficult to design 
and may require customization and new features added. Ultimately, ConnEDCt 
became the study protocol-modeling tool for the research team.  
PSI was a complex study with a very detailed, rules-based schema and 
lengthy CRFs. To ensure data quality a great deal of effort was put into applying 
precise validation rules to ensure values fell into controlled ranges.[57] Many of 
these validation rules also referenced other variables, creating complex 
dependencies. Implementing the rules required a great deal of testing and 




references and other design or coding issues. The effectiveness of these rules, as 
well as their complexity, demonstrated the value of having technical resources 
available during the study design process.[57] 
New feature development for this study focused on dynamically 
generated CRFs and integration with external systems. In this case most of these 
features were executed as custom programming. While some new concepts were 
identified as being important to the framework, because of the limited timeframe 
little of the custom programming was incorporated into the framework during 
the implementation of the study. The dynamic CRF features were later 
implemented as framework elements and used in the MBFC study. These 
dynamic CRF creation events are triggered either upon completion of a CRF or 
triggered during the scheduling procedure to evaluate a condition when 
additional CRFs should be generated.  
The PSI study protocol designates two sets of CRFs, defined by whether 
the participant had a history of pregnancy. The number of past pregnancies is 
captured in the health history CRF. When an RA signes the CRF, the event 
triggers the creation of a number of new pregnancy CRFs, based on the total 
number of pregnancies. During scheduling a controller evaluates the prior 




CRFs should be created. This pre- and post-processing CRF creation model was 
later adopted as a framework element. 
PSI also required integration with an external system that stored census 
data of the cohort of potential participants. RAs used the census tool to create 
participants in ConnEDCt. The census tool created a JSON data object payload 
with participant identity and demographic data and delivered it to an external 
hook in ConnEDCt. Upon receiving the JSON payload, ConnEDCt parses it, and 
creates the participant record and the study ID. RAs conducted informed consent 
and eligibility screening in ConnEDCt to complete participant enrollment.  
The PSI study began recruiting in June of 2018 and was completed in July 
of 2019. Because of the thorough design phase, no adjustments to the data 
schema were made during the data capture phase of the study and little post-
deployment support was needed. 
5.5. Effect Of Multiple Biofortified Food Crops On Micronutrient Status, 
Immune, And Cognitive Function Among Indian Infants 
“Iron, zinc, and vitamin A deficiency remain a major worldwide public 
health problem especially in developing countries.”[60] MBFC is an RCT to 
compare young children consuming meals prepared with multiple biofortified 




changes, and immune function.”[60] 
MBFC followed closely the protocols established with the PMB trial with a 
few exceptions. The close adherence to a previously implemented protocol 
allowed us to focus efforts on streamlining the implementation procedure, 
implementing style sheets for the CRFs, improving workflows such as 
scheduling and device registration, and building user interfaces to manage some 
data such as coded lists, that previously had been managed on the back-end.  
Significant changes were made to the CRF scheduling procedure. In the 
previous PMB study RAs had manually scheduled each visit. For MBFC, 
ConnEDCt automated the scheduling of the entire protocol after randomization. 
The use of randomized midline serial-sampled CRFs required scheduling to 
occur after the randomization of eligible participants. The DM randomized 
participants centrally by manually triggering the randomization of eligible 
participants in batches. The randomization process would then automatically 
trigger the scheduling process. 
Another improvement was to automate the device registration process. 
Because ConnEDCt works off-line with a decentralized study ID numbering 
scheme, each device that runs ConnEDCt has a serialized ID of its own that is 




other words each device is assigned a unique serialized number, like 1, 2, 3, etc. 
The registration process was improved so that devices could self-assign their 
device ID and prompt a data manager to validate the registration status. 
After being tested in the clinical environment, MBFC underwent extensive 
revisions to CRFs, including adding variables, removing variables, moving 
variables to other CRFs, removing CRFs, adding new CRFs, changing the visits 
that CRFs are scheduled in, and changing eligibility formulae. 
MBFC had more user errors than other studies, including data being 
entered in the wrong scheduled visit several times – RAs used the correct CRF, 
but in the wrong visit. The error was corrected by manually moving the CRF 
record to the correct scheduled visit or by clearing all data in the record and the 
RA re-recording the CRF. Such errors rarely happened in prior studies, yet it 
indicated that users need more help identifying and navigating to the correct 
visit. The MBFC trial began recruiting in March 2019 and is ongoing. 
5.6. Environmental Determinants of KSHV in Uganda 
This longitudinal cohort study looks at Kaposi’s sarcoma herpes virus, the 
causative agent of Kaposi’s sarcoma, and its association with malaria infection, 
with the goal of identifying strategies for the prevention of this type of 




framework several features that had been conceived of previously, but had not 
been implemented or had been implemented only as custom code. These 
standardized features included dynamically generated CRFs, better scheduling 
automation, and an agenda view of participant appointments. 
Because the EDKU study schema also required CRFs being generated 
dynamically based on captured data in real time, dynamic CRF generation has 
been incorporated into the pre-processing controller in the CRF generation 
process and the post-processing controller of the CRF signing process. These are 
now framework features that are easy to implement when a study schema 
requires. 
To make the scheduling process more user and participant-friendly 
ConnEDCt now requests a preferred day of the week and a time of day and then 
schedules visits adaptively. Scheduling is triggered manually for each participant 
after eligibility is confirmed so that the RAs can confirm the best appointment 
days and times with the participant.  
The agenda view (figure 4.11) provides a daily or weekly view of 
appointments to help RAs avoid selecting a visit from the wrong date. In 
addition the visit closest to the current date in the visit list interface (figure 4.9) is 




The EDKU study reaffirmed the need for a more flexible data model for 
participants. The study tracks mother/child dyads, whereas ConnEDCt had been 
designed to track only individual participants, so we adapted ConnEDCt to store 
mother and child information. However, adopting the well-established party 
data model[62] would provide a more effective way of linking family members 
and other participant associations. The EDKU study began recruiting in February 




6. FUTURE ENHANCEMENTS 
Implementing ConnEDCt for three clinical surveys and three RCTs 
provided broad experience with varying protocols and plenty of inspiration for 
improving the framework. Some features were placed on the development 
roadmap from early in the planning process, and others have been uncovered 
along the way. 
6.1. Investigator-defined Study Schema 
From the beginning the need to reduce developer involvement in 
implementing a study schema became apparent in order to scale the use of 
ConnEDCt. The more studies that can be implemented in a shorter time, the 
lower cost of each implementation, the less reliance on finite resources, and the 
more flexibility for researchers. CRF development has been the most time-
intensive aspect of every ConnEDCt implementation. The back-and-forth 
between study designers and software developers takes many rounds before a 
design can be finalized. Iteration is simply a part of the study design process. 
Even finalized designs are frequently revised once study recruitment has begun. 
Revisions of the CRF design should be within the control of study designers.  
The present data dictionary design document is too abstract for study 




build a design tool to construct the data dictionary that translates automatically 
into usable CRFs. This ConnEDCt design tool will allow study designers to 
define variables and data validation to directly generate the end result forms. 
Custom development will still be required from time to time to implement new 
ideas for innovative protocols. However, providing a tool that allows designers 
to construct the meta-data associated with a basic study schema would provide 
two advantages. First, it will reduce or eliminate developer involvement in the 
study protocol design phase, and therefore lower costs. Second, it will allow the 
study designers to test and iterate their designs rapidly and thus save time.  
6.2. Statistics and Reporting 
Better statistics availability will help RAs and data managers keep track of 
study progress during the data capture phase of studies. ConnEDCt currently 
shows numbers of eligible, incomplete, and ineligible participants. To get other 
stats DMs must export datasets and run their own analysis to get more in-depth 
information. A dashboard view on opening can provide a useful overview of the 
study. Helpful stats will be the number of enrolled participants in each study 
group, the number of dropouts, and the number of appointment no-shows with 
links to the participants to help RAs follow-up. Breaking out informed consent as 




consent versus other eligibility factors. Viewing other data over time, such as 
enrollment trends or missed appointments, can help manage the performance of 
the study staff or communication issues with participants. A dashboard will 
provide simple real-time statistics and eliminate the need for data exporting and 
analysis to get key performance indicators on the study progress. 
The CONSORT Statement[63] is a formalized, respected reporting format 
for RCTs developed by a group of scientists and editors that includes a checklist 
and a flowchart to avoid systemic error in the assessment of study results. 
CONSORT has been supported by hundreds of academic journals “to provide 
guidance to authors about how to improve the reporting of their trials.”[64] 
Because the CONSORT Statement is structured information consisting of a table 
and a flow chart (figure 6.1), the format can be readily constructed in template 
form. Some information can be directly derived from data that ConnEDCt 
captures or generates. The rest can be presented in a template form for the 
investigators to complete. The full CONSORT Statement can then be exported or 









6.3. Electronic Signatures for Informed Consent 
ConnEDCt supports electronic signatures for users of the system, 
including DMs and RAs, but not participants who are not direct users of 
ConnEDCt. This lack of support for participants’ e-signatures is driven primarily 
by the challenge of determining the authenticated identity of participants as 
defined for electronic systems.  
Providing support for participants’ electronic signatures would make the 
informed consent process completely electronic, totally eliminating the need for 
paper records. Username and password combinations authenticate study 
investigators. Username and password authentication validates electronic 
signatures under current regulations. However, since participants are not 
assigned user accounts in ConnEDCt, another method must validate identities 
within the electronic system. This is especially challenging in an offline context. 
Some options we will consider for creating validated electronic signatures for 
participants are photo or video capture of physical identity verification, such as 
an identity card, along with witness attestation and biometrics validated with 




6.4. Improved Data Transport and Integrations 
Data transport to external statistics packages has been challenging. While 
the Microsoft Excel format seems to be universally accepted, some issues such as 
column headers and null values are not fully resolved. Other options will be 
explored, including translation to native file formats. 
We are actively developing an integration solution to acquire machine-
generated lab results and link them with participants. Few laboratory devices 
support direct integration, so we are prioritizing an import methodology for the 
data files generated by lab devices. DMs will be able to select the data file, 
expunge irrelevant headers, customize column mapping, and associate sample 
IDs with participant CRFs. 
6.5. Data Model Flexibility 
With FeverPhone and EDKU, we adapted ConnEDCt to support 
parent/child dyads in the data single-table entity that stores participant data. 
This functioned well enough but was not ideal. In two opportunities for census 
enumeration where households and family groups were to be enumerated 
together, ConnEDCt was deemed unsuitable for data capture due to the rigidity 
of the single-table entity for tracking participants. 




relationships between participants such as parent/child dyads, family groups, 
households, and other relationships. Adopting the party data model will expand 
the scope of ConnEDCt’s data capture utility. 
All of the studies that employed ConnEDCt required some extent of 
localization of language. UI elements were presented in a local language only, 
English with modifications for dialect, or both English and a local language side 
by side. This applied to the interview questions, coded list options, and UI 
navigational elements. Localization features built into the investigator-defined 
data model will allow study designers to have full control over these elements as 
well as provide users with a choice of localization option. Therefore, Spanish-
speaking users, for example, can view the interface in Spanish, while English-
speaking users can view the same interface in English. 
6.6. Automated Updates 
Even with the investigator defined study schema and flexible data model, 
experience has shown that there will be customizations made post-deployment 
that will require updates. The current update process requires users to replace 
files on their devices manually. An automated update process would involve 
detecting the existence of an update, verifying the sync status, optionally 




and replacing the old database file. This process could be completed with 
minimal user-interaction with a user prompt to begin and a confirmation notice 
at the end.  
6.7. Documentation 
Finally, we have developed several standard operating procedure (SOP) 
documents for ConnEDCt. These SOPs will be collected and organized into a 
volume of comprehensive documentation. While ConnEDCt is intuitive to use 
and requires little training, the need for documentation is evident from the 
repetition of some of the same questions new users ask. In addition the U.S. 
Department of Health and Human Services has published non-binding 
recommendations regarding documentation of electronic records systems.[66] 
Some of the current SOPs, such as those for deploying updates, will become 
obsolete when features described in this chapter are completed, yet some 






In Chapter 1, I introduced the elements of clinical data capture protocols 
and ConnEDCt, the software framework I built in cooperation with clinical 
investigators to support complex EDC protocols in resource-constrained areas. 
But what makes ConnEDCt a framework? A software framework should provide 
context-specific yet generic features that can be further adapted to additional 
requirements. The framing elements for clinical electronic data capture include 
data security and integrity, consent forms, eligibility criteria, visit scheduling, 
CRFs, and randomization with study groups. ConnEDCt provides an 
implementation framework that supports these features on a mobile platform 
and it has been expanded with customized features during almost every 
implementation process. 
After implementing six successful and highly differentiated study 
protocols, ConnEDCt has proven to be an effective EDC framework. It has 
provided standard study protocol features and compliance with government 
regulations, while the framework architecture has supported feature expansion. 
With nearly every new implementation, new opportunities have been uncovered 
to add greater sophistication to ConnEDCt while maintaining its underlying 




features like randomized serial sampling and contingent CRFs. The six successful 
implementations for research in resource-constrained locations, have proven 
ConnEDCt’s effectiveness and flexibility[53-61]. 
ConnEDCt has demonstrated value for investigators who wish to perform 
research in remote areas where internet is unreliable and for those who need 
advanced protocol support. While ConnEDCt will benefit from improvements in 
user-defined schema definition, real-time stats, and some other areas, we are 
actively improving it and hope to raise the visibility of ConnEDCt as a 
commercial option for clinical EDC. 
ConnEDCt is far more advanced than the tool I created for the TBI survey 
in the late 1990s and includes features for protocol enforcement, offline function, 
and flexibility that other popular EDC tools, including the highly popular 
REDCap[19], lack. Although information technology has evolved tremendously 
since then, there are still poor, resource-constrained geographical areas that 
suffer not just from lack of pervasive internet but also from what many of us 
would consider basic healthcare backed by medical science. ConnEDCt is a 
flexible platform that prioritizes mobility, is adaptable to different study 
protocols, has extensive study protocol support built-in, and functions on- or 




clinical research needs with a focus on mobility and flexibility. I intend to 
continue with the development of ConnEDCt and the engagement with clinical 
researchers, thereby supporting clinical research, especially those studies 
conducted in rural or resource-constrained areas, and improving clinical 




APPENDIX A: Selected Schema Entities’ Attributes 
Note that FileMaker data types do not conform to standard SQL data types. 
Number and text are valid FileMaker data type definitions. 
Device table  













Appendix A: Table 1. Device table attributes 
 
EligibilityCriterion table  


















Appendix A: Table 3. PartEligibilityCriterion table attributes 
 
VisitType table  







Appendix A: Table 4. VisitType table attributes 
 
FormSchedule table  












PartEventForm table  










Appendix A: Table 6. PartEventForm table attributes 
 
StudyGroup table  




Appendix A: Table 7. StudyGroup table attributes 
 
Randomization table  












APPENDIX B: Case Studies Tabular Data 
Case studies schema 
metrics VDTB PMBT FeverPhone PSI MBFC KSHV 
CRFs 19 19 10 64 23 14 
Variables 881 753 386 3239 808 354 
Consent forms 2 3 3 1 1 1 
Scheduled visits 14 11 3 6 11 19 
Scheduled CRF instances 66 101 18 66 154 59 
Eligibility criteria 9 13 3 5 15 4 
coded lists 93 73 30 112 104 26 
Randomized study 
groups 4 2 0 0 4 0 
Appendix B: Table 1. Case studies schema metrics 
 
Case studies data 
capture metrics PMBT FeverPhone PSI MBFC KSHV VDTB 
status completed ongoing completed completed ongoing 
not 
started 




devices (iPads) 4 5 17 12 5 - 
Screened 
participants 408 436 2888 345 131 - 
Participant 
encounters 
(checked-in) 1890 938 8728 1711 354 - 
Participant 
encounters 
(scheduled) 2612 938 17305 3323 1453 - 
Signed CRFs 9851 3304 29025 12870 761 - 
Scheduled CRFs 19660 5108 41683 26310 4369 - 
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